Zenith Alpha™ Abdominal Endovascular Graft
- Conditions
- Aorto-iliac AneurysmAbdominal Aortic
- Registration Number
- NCT03061825
- Lead Sponsor
- Cook Research Incorporated
- Brief Summary
The purpose of this study is to evaluate the clinical performance of the Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- A patient is considered eligible for inclusion in the study if the patient has an infrarenal abdominal aortic or aorto-iliac aneurysm and is intended to be treated with the Zenith Alpha™ Abdominal Endovascular Graft
- Life expectancy less than (<) 2 years
- Inability or refusal to give informed consent by the patient or legally authorized representative
- Unwilling or unable to comply with the study follow-up
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Device Success 2 years Technical success (successful introduction and deployment of the device in the absence of surgical conversion or mortality) plus freedom from the following: abdominal aneurysm rupture, conversion, Type I or III endoleak, graft limb occlusion and abdominal aneurysm size increase \> 5 mm.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
London Health Sciences Center
🇨🇦London, Ontario, Canada
Hamilton General Hospital
🇨🇦Hamilton, Ontario, Canada
Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
Nova Soctia Health Authority
🇨🇦Halifax, Nova Scotia, Canada
Vancouver Hospital and Health Science Center
🇨🇦Vancouver, British Columbia, Canada